"Methotrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
| Descriptor ID |
D008727
|
| MeSH Number(s) |
D03.633.100.733.631.192.500
|
| Concept/Terms |
Methotrexate Sodium- Methotrexate Sodium
- Sodium, Methotrexate
- Methotrexate, Sodium Salt
- Methotrexate, Disodium Salt
|
Below are MeSH descriptors whose meaning is more general than "Methotrexate".
Below are MeSH descriptors whose meaning is more specific than "Methotrexate".
This graph shows the total number of publications written about "Methotrexate" by people in this website by year, and whether "Methotrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 5 | 6 |
| 1999 | 0 | 2 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 3 | 4 | 7 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 1 | 3 | 4 |
| 2009 | 1 | 7 | 8 |
| 2010 | 0 | 5 | 5 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 3 | 3 |
| 2013 | 5 | 3 | 8 |
| 2014 | 2 | 0 | 2 |
| 2015 | 3 | 7 | 10 |
| 2016 | 1 | 5 | 6 |
| 2017 | 5 | 5 | 10 |
| 2018 | 5 | 2 | 7 |
| 2019 | 4 | 2 | 6 |
| 2020 | 2 | 5 | 7 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 6 | 7 |
| 2023 | 1 | 3 | 4 |
| 2024 | 3 | 3 | 6 |
| 2025 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methotrexate" by people in Profiles.
-
Phytoconstituents as therapeutic agents in combating methotrexate-induced hepatotoxicity and nephrotoxicity. Expert Opin Drug Metab Toxicol. 2025 Nov-Dec; 21(11-12):1287-1305.
-
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
-
What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric Malignancies. Pediatr Blood Cancer. 2025 Jul; 72(7):e31744.
-
High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi. JCO Glob Oncol. 2025 Mar; 11:e2400591.
-
Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country. JCO Glob Oncol. 2025 Mar; 11:e2400450.
-
Infantile myofibromatosis: Small bumps pose big problems. J Neonatal Perinatal Med. 2025 Mar; 18(2):179-183.
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
-
Methotrexate: Borrowed Hope for Persons With Knee Osteoarthritis? Ann Intern Med. 2024 Sep; 177(9):1271-1272.
-
Late-life dietary folate restriction reduces biosynthesis without compromising healthspan in mice. Life Sci Alliance. 2024 Oct; 7(10).
-
Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 Oct; 71(10):e31213.